Overview

Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy

Status:
Completed
Trial end date:
2019-09-05
Target enrollment:
Participant gender:
Summary
Study to evaluate the Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy
Phase:
Phase 3
Details
Lead Sponsor:
Octapharma